A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) (NCT06679101)

🧪 Interventions in This Study

• Belantamab mafodotin (DRUG)
• Lenalidomide (DRUG)
• Dexamethasone (DRUG)
• Daratumumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (181 Sites)

Showing the first 25 of 181 sites.

• GSK Investigational Site — Mobile, Alabama
• GSK Investigational Site — Phoenix, Arizona
• GSK Investigational Site — Beverly Hills, California
• GSK Investigational Site — Pasadena, California
• GSK Investigational Site — Aurora, Colorado
• GSK Investigational Site — Washington D.C., District of Columbia
• GSK Investigational Site — Englewood, Florida
• GSK Investigational Site — Lady Lake, Florida
• GSK Investigational Site — Pembroke Pines, Florida
• GSK Investigational Site — Saint Augustine, Florida
• GSK Investigational Site — Atlanta, Georgia
• GSK Investigational Site — Portland, Maine
• GSK Investigational Site — Worcester, Massachusetts
• GSK Investigational Site — Ann Arbor, Michigan
• GSK Investigational Site — Detroit, Michigan
• GSK Investigational Site — Billings, Montana
• GSK Investigational Site — Hackensack, New Jersey
• GSK Investigational Site — New York, New York
• GSK Investigational Site — Stony Brook, New York
• GSK Investigational Site — Charlotte, North Carolina
• GSK Investigational Site — Winston-Salem, North Carolina
• GSK Investigational Site — Columbus, Ohio
• GSK Investigational Site — Providence, Rhode Island
• GSK Investigational Site — Austin, Texas
• GSK Investigational Site — Austin, Texas

📞 Contact the Study Coordinator

Phone: (877) 379-3718

Email: GSKClinicalSupportHD@gsk.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.